| Ytd | -11.67% | |
| 1y | 71.37% |
| Open | 539.67 | Prev Close | 536.95 | Low | 512.75 | High | 542.97 | Mkt Cap | 11.86B |
| Vol | 303.74K | Avg Vol | 328.33K | EPS | -13.48 | P/E | N/A | Forward P/E | 41.55 |
| Beta | -1.06 | Short Ratio | 14.11 | Inst. Own | 106.48% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 508.68 | 200-d Avg | 496.57 | 1yr Est | 678.71 |
MDGL News
/PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (06938.HK) y su filial Ribocure Pharmaceuticals A
SUZHOU, China and MÖLNDAL, Sweden, July 1, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (
B of A Securities analyst Alexandria Hammond maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) wit
Growing body of clinical and real-world evidence supports the role of Rezdiffra® (resmetirom) as the
Truist Securities analyst Srikripa Devarakonda maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) w
Canaccord Genuity analyst Edward Nash maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy
Evercore ISI Group analyst Liisa Bayko maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Ou
HC Wainwright & Co. analyst Andrew S. Fein reiterates Madrigal Pharmaceuticals (NASDAQ:MDGL)
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(3.25) per share which beat the
- Precision approach targets patients who have a mutation in the PNPLA3 gene, which is highly preval
Company advances its leadership in MASH with clinical-stage, genetically targeted siRNA asset from A
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering nove
Barclays analyst Eliana Merle initiates coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a
Citizens analyst Jonathan Wolleben maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Market
A wave of analyst downgrades, outlook resets and company-specific headlines pushed last week's b
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering nov
Piper Sandler analyst Yasmeen Rahimi maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Over
B. Riley Securities analyst William Woods maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a
HC Wainwright & Co. analyst Andrew S. Fein maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) w
Oppenheimer analyst Jay Olson maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Outperform
Truist Securities analyst Srikripa Devarakonda maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) w
Canaccord Genuity analyst Edward Nash maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy
HC Wainwright & Co. analyst Andrew S. Fein maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) w
Rezdiffra® treatment significantly improved liver stiffness, fibrosis biomarkers, and markers of cli
Expedia, SanDisk, and Penumbra led last week's large-cap gainers, with strong earnings and raise
Cantor Fitzgerald analyst Prakhar Agrawal upgrades Madrigal Pharmaceuticals (NASDAQ:MDGL) from Ne
Citizens analyst Jonathan Wolleben maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Market
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(5.08) per share which missed t
B of A Securities analyst Alexandria Hammond upgrades Madrigal Pharmaceuticals (NASDAQ:MDGL) from
Two oral presentations to highlight biomarker, imaging and quality-of-life data from the open-label
Piper Sandler analyst Yasmeen Rahimi maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Over
Truist Securities analyst Srikripa Devarakonda initiates coverage on Madrigal Pharmaceuticals (NA
Oppenheimer analyst Jay Olson maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Outperform
Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets i
In the latest quarter, 7 analysts provided ratings for Madrigal Pharmaceuticals (NASDAQ: MDGL), show
B. Riley Securities analyst Mayank Mamtani maintains Madrigal Pharmaceuticals (NASDAQ: MDGL) with
